Welgene Biotech Co Ltd 2024 SR
The report marks Welgene Biotech's inaugural ESG disclosure, detailing its sustainability performance for the 2024 fiscal year. Key highlights include achieving TFDA LDTS certification for five precision medicine molecular testing items and becoming the exclusive distributor for Guardant Health's cancer genetic testing in Taiwan. The company reported a 9.86% increase in revenue and maintained a 100% completion rate for employee information security training. Additionally, Welgene demonstrated a strong commitment to quality management, holding ISO 17025 certification and achieving a 100% customer satisfaction rate in its annual survey.
Company: Welgene Biotech Co Ltd
Year: 2024
Type: SR
Pages: 236
Welgene Biotech Co Ltd
ESG Report
The report marks Welgene Biotech's inaugural ESG disclosure, detailing its sustainability performance for the 2024 fiscal year. Key highlights include achieving TFDA LDTS certification for five precision medicine molecular testing items and becoming the exclusive distributor for Guardant Health's cancer genetic testing in Taiwan. The company reported a 9.86% increase in revenue and maintained a 100% completion rate for employee information security training. Additionally, Welgene demonstrated a strong commitment to quality management, holding ISO 17025 certification and achieving a 100% customer satisfaction rate in its annual survey.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees